The effect of cinnora supplement therapy in patients with severe form of COVID-19

Evaluation of the effect of cinnora supplement therapy in patients with severe form of COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180209038673N6

Enrollment

Registered

2022-04-26

Start date

2022-01-10

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Patients in the intervention group receive standard treatment, including corticosteroids (Abidi Company), 200 mg remdisiver (Ronak Company). Then, they receive 100

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years Patients with definitive diagnosis of COVID-19

Exclusion criteria

Exclusion criteria: Patients who treated with tumour necrosis factor a inhibitors due to previous inflammatory diseases. Positive purified protein derivative skin test. Active bacterial infection.

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptoms (arterial oxygen). Timepoint: Daily evaluation of clinical signs for up to two weeks. Method of measurement: Pulse oximeter.	—

Secondary

Measure	Time frame
C-reactive protein (CRP). Timepoint: Daily evaluation of clinical signs for up to two weeks. Method of measurement: CRP kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Ghavam Nezhad

Kashan University of Medical Sciences

Khadijehghavamnezhad201999@gmail.com+98 31 5544 3022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026